Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.

Gagner JP, Sarfraz Y, Ortenzi V, Alotaibi FM, Chiriboga LA, Tayyib AT, Douglas GJ, Chevalier E, Romagnoli B, Tuffin G, Schmitt M, Lemercier G, Dembowsky K, Zagzag D.

Am J Pathol. 2017 Sep;187(9):2080-2094. doi: 10.1016/j.ajpath.2017.04.020. Epub 2017 Jul 20. Erratum in: Am J Pathol. 2017 Nov;187(11):2617.

2.

POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.

Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P.

Oncotarget. 2015 Oct 13;6(31):30902-18. doi: 10.18632/oncotarget.5094.

3.

CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.

Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN.

Mol Cancer Ther. 2015 Nov;14(11):2473-85. doi: 10.1158/1535-7163.MCT-15-0252. Epub 2015 Aug 12.

4.

Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption.

Suenderhauf C, Tuffin G, Lorentsen H, Grimm HP, Flament C, Parrott N.

Pharm Res. 2014 Oct;31(10):2696-707. doi: 10.1007/s11095-014-1367-6. Epub 2014 May 3.

PMID:
24792825
5.

Podocyte EphB4 signaling helps recovery from glomerular injury.

Wnuk M, Hlushchuk R, Janot M, Tuffin G, Martiny-Baron G, Holzer P, Imbach-Weese P, Djonov V, Huynh-Do U.

Kidney Int. 2012 Jun;81(12):1212-25. doi: 10.1038/ki.2012.17. Epub 2012 Mar 7.

6.

The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRβ pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis.

Wnuk M, Hlushchuk R, Tuffin G, Huynh-Do U, Djonov V.

Am J Pathol. 2011 Apr;178(4):1899-912. doi: 10.1016/j.ajpath.2010.12.049.

7.

Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis.

Suana AJ, Tuffin G, Frey BM, Knudsen L, Mühlfeld C, Rödder S, Marti HP.

J Pharmacol Exp Ther. 2011 May;337(2):411-22. doi: 10.1124/jpet.110.176222. Epub 2011 Feb 24.

PMID:
21349934
8.

Lipopolysaccharide induces intestinal glucocorticoid synthesis in a TNFalpha-dependent manner.

Noti M, Corazza N, Tuffin G, Schoonjans K, Brunner T.

FASEB J. 2010 May;24(5):1340-6. doi: 10.1096/fj.09-140913. Epub 2010 Jan 7.

PMID:
20056718
9.

The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies.

Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J.

J Neurochem. 2008 Dec;107(5):1358-68.

10.

Drug targeting using OX7-immunoliposomes: correlation between Thy1.1 antigen expression and tissue distribution in the rat.

Tuffin G, Huwyler J, Waelti E, Hammer C, Marti HP.

J Drug Target. 2008 Feb;16(2):156-66. doi: 10.1080/10611860701848944 .

PMID:
18274936
11.

A new drug-release method using the Staudinger ligation.

Azoulay M, Tuffin G, Sallem W, Florent JC.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3147-9. Epub 2006 Apr 18.

PMID:
16621529
12.

Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney.

Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP.

J Am Soc Nephrol. 2005 Nov;16(11):3295-305. Epub 2005 Sep 21.

Supplemental Content

Loading ...
Support Center